CB1 antagonists (e.g., JD5037—3 mg/kg) were shown to reverse diabetic neuropathy (DN) in mice via modulation of glucose transporter 2 (GLUT-2) expression and activity in renal proximal tubule cells [230,231]. The gene discussed is CNR1; the disease is liver dysplastic nodule.